### Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form NT 10-Q

RENHUANG PHARMACEUTICALS INC

Form NT 10-Q September 15, 2010

UNITED STATES OMB APPROVAL

SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.C. 20549 Expires: May 31, 2012

Estimated average burden

hours per response . . . . . . 2.50

FORM 12b-25 SEC FILE NUMBER

001-34808

NOTIFICATION OF LATE FILING

**CUSIP NUMBER** 

(Check one): "Form 10-K "Form 20-F "Form 11-K x Form 10-Q "Form 10-D "Form N-SAR "Form N-CSR

For Period Ended: July 31, 2010

- " Transition Report on Form 10-K
- " Transition Report on Form 20-F
- " Transition Report on Form 11-K
- " Transition Report on Form 10-Q
- " Transition Report on Form N-SAR

For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above identify the Item(s) to which the notification relates:

#### PART I – REGISTRANT INFORMATION

Renhuang Pharmaceuticals, Inc. Full Name of Registrant

Former Name if Applicable The 11th Floor, Changjiang International Building, No. 28 Changjiang Road, Nangang District, Harbin Address of Principal Executive Office (Street and Number)

Heilongjiang Province, P.R. China 150090 City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be

# Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form NT 10-Q

completed. (Check box if appropriate.)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

### PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.

Information necessary for the filing of a complete and accurate report on Form 10-Q could not be gathered within the prescribed time period without unreasonable effort and expense.

## Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form NT 10-Q

# PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Li Shaoming

86

451-8260-2162

(Name) (Area Code)

(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes x No "

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes" No x

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Renhuang Pharmaceuticals, Inc. (Name of Registrant as specified in its charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 15, 2010 By: /s/ Li Shaoming

Li Shaoming, Chief Executive Officer